Weight and menstrual recovery improve bone density in anorexia nervosa
A 2014 review of studies in adults and adolescents concludes that in anorexia nervosa, regaining weight and menstrual function improves bone density most. The illness is associated with low bone density and a higher risk of fracture. In an 18-month randomized trial, adolescent girls given transdermal estradiol with cyclic progesterone kept their bone density Z-scores steady.
Key Findings
In community-dwelling adult women with anorexia nervosa, more than 90% had T-scores below −1 and close to 40% had T-scores below −2.5 at one or more sites.
Among adolescent girls, 31% with anorexia nervosa reported one or more past fractures, compared with 19% of normal-weight healthy controls.
In adult women, weight gain with menstrual recovery led to bone density rising by a mean of 3.1% a year at the spine and 1.8% a year at the hip.
In an 18-month randomized trial of adolescent girls, transdermal estradiol with cyclic progesterone raised bone accrual to approximate normal-weight control rates and kept Z-scores steady; Z-scores fell on placebo.
In one-year randomized trials, risedronate raised spine and hip bone density by 3% and 2% in adult women, and alendronate did not improve spine bone density in adolescents.
Interpretation
The article is a review by researchers at Massachusetts General Hospital. It brings together comparisons with healthy controls, follow-up studies, and randomized trials of single treatments in girls, women, boys, and men with anorexia nervosa. T-scores and Z-scores compare a person's bone density with healthy reference groups. Adolescents who regained weight and menses improved, although complete catch-up did not occur. Most studies of oral estrogen-progesterone combination pills found no gain in bone density in adults or adolescents. The authors note that most data come from studies using the earlier DSM IV criteria, and the effect of the 2013 DSM V criteria remains unknown.
RRM Context
RRM treats a loss of ovulation as a finding with a cause, and Creighton Model charting records the signs of ovulation. The review calls suppression of the reproductive axis advantageous when energy availability is very low. It names low estradiol and amenorrhea duration as key factors in low bone density. The 18-month trial used micronized progesterone, and ovulation makes the body's own estradiol and progesterone, while combination pills contain synthetic progestins.
Our editorial summary of this paper, not the article's abstract.
Abstract
Anorexia nervosa (AN) is a condition of severe low weight that is associated with low bone mass, impaired bone structure, and reduced bone strength, all of which contribute to increased fracture risk. Adolescents with AN have decreased rates of bone accrual compared with normal-weight controls, raising additional concerns of suboptimal peak bone mass and future bone health in this age group. Changes in lean mass and compartmental fat depots, and hormonal alterations secondary to nutritional factors contribute to impaired bone metabolism in AN. The best strategy to improve bone density is to regain weight and menstrual function. Oral estrogen-progesterone combinations are not effective in increasing bone density in adults or adolescents with AN, and transdermal testosterone replacement is not effective in increasing bone density in adult women with AN. However, physiological estrogen replacement as transdermal estradiol with cyclic progesterone does increase bone accrual rates in adolescents with AN to approximate that in normal-weight controls, leading to a maintenance of bone density Z-scores. A recent study has shown that risedronate increases bone density at the spine and hip in adult women with AN. However, bisphosphonates should be used with great caution in women of reproductive age, given their long half-life and potential for teratogenicity, and should be considered only in patients with low bone density and clinically significant fractures when non-pharmacological therapies for weight gain are ineffective. Further studies are necessary to determine the best therapeutic strategies for low bone density in AN.
Bone Health › Bone Mineral Density › Peak Bone Mass · Therapeutics › Hormonal Agents › Estrogen Preparations · Reproductive Endocrinology › Ovarian Hormones › Estrogen
Madhusmita Misra, Anne Klibanski
M Misra, A Klibanski
PMID 24898127 24898127 DOI 10.1530/JOE-14-0039 10.1530/JOE-14-0039 Misra et al. 2014, Misra 2014